| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/02/2001 | CA2397267A1 Peptide fragments and uses thereof as type-1 interferon antagonist |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2396596A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | CA2395730A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | CA2394525A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 08/02/2001 | CA2394332A1 Chimeric neuropeptide y receptors |
| 08/02/2001 | CA2394292A1 Isatine derivatives with neurotrophic activity |
| 08/02/2001 | CA2297706A1 Anticonvulsive and antiallergic/anti-asthmatic pyrazolo-(3,4-d)pyrimidines having affinity for the adenosine receptor, and process for their preparation |
| 08/01/2001 | EP1120723A2 Identification of the cytochrome P-450 inhibitory potency of neurokinin-1 receptor antagonists and associated pharmacophore models and screening methods |
| 08/01/2001 | EP1120466A2 Use of negative regulation elements for nerve-specific expression of transgenes |
| 08/01/2001 | EP1120417A2 Xanthine derivatives for the treatment of cerebrovascular disorders |
| 08/01/2001 | EP1120416A1 Pyrido[2.3-b][1,4]benzodiazepinones as M2 receptor ligand for the treatment of neurological disorders |
| 08/01/2001 | EP1120410A1 Nicotinic acid esters useful as CNS agents and having affinity for 5-HT receptors |
| 08/01/2001 | EP1119772A1 A novel ret-independent signaling pathway for gdnf |
| 08/01/2001 | EP1119629A2 Oxidoreductase molecules |
| 08/01/2001 | EP1119620A2 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses |
| 08/01/2001 | EP1119619A2 Nlk1 -interacting proteins |
| 08/01/2001 | EP1119573A2 Bipyridine manganese complexes |
| 08/01/2001 | EP1119571A2 Tricyclic delta3-piperidines as alpha2-antagonists |
| 08/01/2001 | EP1119570A1 Tricyclic delta3-piperidines as pharmaceuticals |
| 08/01/2001 | EP1119564A1 Aryl- 4-fluoro-4- (2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl -methanone derivatives as 5-ht1 receptor antagonists |
| 08/01/2001 | EP1119563A1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119562A1 2,3-dihydro-1h-isoindole derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 08/01/2001 | EP1119555A1 Biphenylene lactams as prostaglandin receptor ligands |
| 08/01/2001 | EP1119553A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 08/01/2001 | EP1119552A1 Ureidopiperidine derivatives as selective human nk 3? receptor antagonists |
| 08/01/2001 | EP1119551A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP1119550A1 2-substituted heterocyclic sulfonamides |
| 08/01/2001 | EP1119548A1 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 08/01/2001 | EP1119543A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 08/01/2001 | EP1119542A1 Prostaglandin receptor ligands |
| 08/01/2001 | EP1119538A1 Derivatives of phenantrene for medicinal use and a process for their preparation |
| 08/01/2001 | EP1119366A1 Animal stereotypy |
| 08/01/2001 | EP1119363A2 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 08/01/2001 | EP1119359A1 2-methyl-thieno-benzodiazepine formulation |
| 08/01/2001 | EP1119357A1 C3a receptor ligands |
| 08/01/2001 | EP1119355A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 08/01/2001 | EP0885013B1 Use of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses for the preparation of medicaments |
| 08/01/2001 | EP0862567B1 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 08/01/2001 | EP0737074B1 Botulinum toxins for treating hyperhydrosis |
| 08/01/2001 | EP0719268B1 K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY |
| 08/01/2001 | EP0691846B1 Imidazolo-quinoxalinones for treating diseases of the central nervous system |
| 08/01/2001 | EP0631503B1 Use of vasoactive intestinal peptide (vip) to induce temporary paralysis of the gastrointestinal tract |
| 08/01/2001 | CN1306576A G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 08/01/2001 | CN1306541A Compound for unstable dipeptidyl peptidase IV inhibitors |
| 08/01/2001 | CN1306540A Prodrugs of dipeptidyl peptidase IV inhibitors |
| 08/01/2001 | CN1306532A Novel pyrrolo-(3,4-B) quinoline derivatives, method for prodn. and use thereof as medicament |
| 08/01/2001 | CN1306530A Paroxetine 10-camphorsulfonate for treament of CNS disorders |
| 08/01/2001 | CN1306529A Novel form of irbesartan, methods for obtaining said form and pharmaceutical compsns. contg. same |
| 08/01/2001 | CN1306526A Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 08/01/2001 | CN1306525A Carboxylic acid of aza-heterocyclic compounds contg. multiple hetero-atoms or its electronic isosteric object |
| 08/01/2001 | CN1306512A Heterocyclic inhibitors of P38 |
| 08/01/2001 | CN1306511A Novel heterocyclic compounds |
| 08/01/2001 | CN1306509A Substituted benzamides, their prodn. and use as cysteine protease inhibitors |
| 08/01/2001 | CN1306505A Substituted benzamides, their prodn. and use |
| 08/01/2001 | CN1306503A 2-fluoro-2-alkyl alkanoamides with anticonvulsant activity |
| 08/01/2001 | CN1306428A Inhibitors of transcription factor NF-KB |
| 08/01/2001 | CN1306427A Acylbenzoxazines for enhancing synaptic response(s) |
| 08/01/2001 | CN1306424A Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treatment of neurogenic inflammation |
| 08/01/2001 | CN1305993A Cyclic guanyl preparation used as nitrogen oxide synthetic enzyme inhibitor |
| 08/01/2001 | CN1305989A Benzene sulfonamide compounds, its preparing method and medicinal compsns. contg. same |
| 08/01/2001 | CN1305838A Atomized inhalation for treating headache |
| 08/01/2001 | CN1305825A Health-care oral liquid for giving up smoking |
| 08/01/2001 | CN1305812A N-(aryloxy group alkyl) heteroaromatic guadine and heteroaromatic guazine used as medicines |
| 08/01/2001 | CN1305811A Medicinal composition and its antalgic purpose |
| 08/01/2001 | CN1069059C Chinese patent medicine for treating epilepsy |
| 08/01/2001 | CN1069056C Pure chinese medicine for giving up drug |
| 08/01/2001 | CN1069052C Traditional Chinese medicine for curing neurasthenia |
| 08/01/2001 | CN1069040C Extract for dredging channels and collateralls |
| 07/31/2001 | US6268507 Hydantoin derivatives |
| 07/31/2001 | US6268398 Aromatic guanidine derivatives |
| 07/31/2001 | US6268397 Alpha-(1-adamantylaminomethyl)3,4-dichlorobenzyl)thioacetamid e and its isomers, as well as the addition salts of these compounds |
| 07/31/2001 | US6268396 Administering 2-n-propyl-4-hexynoic acid |
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268389 Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268369 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 07/31/2001 | US6268368 Antidepressants |
| 07/31/2001 | US6268362 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 07/31/2001 | US6268355 Stable aspirin-containing preparations for external use |
| 07/31/2001 | US6268347 Alleviating neuropathic pain |
| 07/31/2001 | US6268346 Having high biological activity of the same type as the known natural compound bpc, but with shorter amino acid chains. |
| 07/31/2001 | US6268342 Method of inhibiting fibrosis with a somatostatin agonist |
| 07/31/2001 | US6268340 In vivo regeneration of oligodendrocytes by bolus injection of NGFβ |
| 07/31/2001 | US6268333 Blend with 1,3-dimethoxy-5-methylbenzene; stimulative component is a jasmine formulation. |
| 07/31/2001 | US6268151 Antisense modulation of macrophage migration inhibitory factor expression |
| 07/31/2001 | US6267955 Mononuclear phagocytes and their use to promote axonal regeneration |
| 07/31/2001 | US6267945 Farnesol-related calcium channel blockers |
| 07/31/2001 | CA2282890C Therapeutic heterocyclic compounds |
| 07/31/2001 | CA2218663C Benzisoxazole and indazole derivatives as antipsychotic agents |
| 07/31/2001 | CA2122058C Tgf-beta to improve neural outcome |
| 07/31/2001 | CA2118119C Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 07/31/2001 | CA2068763C Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| 07/31/2001 | CA2035951C Bilobalide derivatives, their applications and formulations containing them |
| 07/26/2001 | WO2001053506A2 Virus strains for the oncolytic treatment of cancer |
| 07/26/2001 | WO2001053505A2 Herpes virus strains for gene therapy |
| 07/26/2001 | WO2001053490A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom |
| 07/26/2001 | WO2001053489A1 Human gaba receptor proteins and polynucleotides encoding the same |
| 07/26/2001 | WO2001053469A2 Phosphatases |
| 07/26/2001 | WO2001053468A2 Lipid metabolism enzymes and polynucleotides encoding them |